SOD1 and amyotrophic lateral sclerosis: Notably, the use of plasma NfL in predicting phenoconversion in presymptomatic carriers of SOD1 variants associated with high or complete penetrance and rapid disease progression has enabled the first interventional trial in presymptomatic ALS [85].